Drug Trial Radar · NCT05577715
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Actual
Start
Nov 14, 2022
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
MORAb-202Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate as Per InvestigatorTime frame: From the date of randomization to the date of first objectively documented progression or death, whichever occurs first (Up to approximately 12 months)
- Number of Participants With Drug -Related Adverse Events Leading to DiscontinuationTime frame: From first dose and 30 days after last dose of study therapy (up to approximately 12 months).
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0007
Orange, California
Local Institution - 0035
Lone Tree, Colorado
Local Institution - 0043
Clermont, Florida
Local Institution - 0010
Orange City, Florida
Local Institution - 0001
Marietta, Georgia
Local Institution - 0005
Louisville, Kentucky
Local Institution - 0044
Silver Spring, Maryland
Henry Ford Hospital
Detroit, Michigan
Local Institution - 0002
Kansas City, Missouri
Local Institution - 0011
Charlotte, North Carolina
Local Institution - 0034
Arlington, Texas
Local Institution - 0045
Flower Mound, Texas
Local Institution - 0033
Fairfax, Virginia
Local Institution - 0040
Wollongong, NS, Australia
Local Institution - 0012
Ballarat Central, Victoria, Australia
Local Institution - 0022
Murdoch, Western Australia, Australia
Local Institution - 0036
Roeselare, Belgium
Local Institution - 0039
Mons, WHT, Belgium
Local Institution - 0030
Independencia, Chile
Local Institution - 0027
Recoleta, Chile
Local Institution - 0023
Santiago, Chile
Local Institution - 0028
Providencia, SA, Chile
Local Institution - 0017
Rouen, France
Local Institution - 0015
Suresnes, France
Local Institution - 0014
Toulon, France
Local Institution - 0038
Villejuif, France
Local Institution - 0025
Barcelona, Spain
Local Institution - 0021
Barcelona, Spain
Local Institution - 0018
Madrid, Spain
Local Institution - 0026
Santiago de Compostela, Spain
Local Institution - 0031
Seville, Spain
Local Institution - 0019
Majadahonda (Madrid), M, Spain
Local Institution - 0020
Málaga, MA, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.